MedeAnalytics sold to private equity firm Thoma Bravo
Deal will give financial analytics firm the leverage to make future acquisitions.
Image from Flickr.
Healthcare analytics platform provider MedeAnalytics on Tuesday said it has sold itself to Thoma Bravo, a private equity firm, for an undisclosed sum.
San Francisco-based Thoma Bravo already holds stakes in Global Healthcare Exchange, a cloud-based provider of supply chain services for healthcare organizations, Mediware Information Systems, which provides technology for managing clinical processes like blood and medication management, and SRS software, an electronic health records platform, in addition to several other tech companies not tied to healthcare.
MedeAnalytics deals mostly with financial monitoring and risk calculation, helping the more than 1,500 providers it serves to find ways to control costs, the company said.
According to the companies, the deal will give MedeAnalytics the financial leverage to make future acquisitions.
Like Healthcare Finance on Facebook
"It was important for us to partner with an investment firm that will support our team as we build on the considerable momentum we have created in the dynamic healthcare analytics space," MedeAnalytics CEO Andy Hurd said in a statement.
While Thoma Bravo will take a majority interest in the company, prior investors Bain Capital Integral Investors and Emergence Capital Partners will continue to hold a minority stake in MedeAnalytics.
[Also: MedeFinance changes name to MedeAnalytics]
Emeryville, California-based MedeAnalytics was previously named MedeFinance before announcing its name change at the 2009 HIMSS Annual Conference.
Twitter: @HenryPowderly
